Molecular markers for bladder cancer: the road to a multimarker approach

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics21(18), 1315–1330 (2003).
   PubMed Web of Science ®Google Scholar
• Livingstone LR, White A, Sprouse J et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell70(6), 923–935 (1992).
   PubMed Web of Science ®Google Scholar
• Allard P, Bernard P, Fradet Y, Tetu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br. J. Urol.81(5), 692–698 (1998).
   PubMedGoogle Scholar
• Althausen AF, Prout GR Jr, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J. Urol.116(5), 575–580 (1976).
   PubMed Web of Science ®Google Scholar
• Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J. Urol.127(2), 250–252 (1982).
   PubMed Web of Science ®Google Scholar
• Steven K, Poulsen AL. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J. Urol.178(4), 1218–1224 (2007).
   PubMed Web of Science ®Google Scholar
• Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol.24(35), 5552–5564 (2006).
   PubMed Web of Science ®Google Scholar
• Carmack AJ, Soloway MS. The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology67(3 Suppl. 1), 3–8; discussion 8–10 (2006).
   PubMed Web of Science ®Google Scholar
• Lane DP. p53, guardian of the genome. Nature358(6381), 15–16 (1992).
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science253(5015), 49–53 (1991).
   PubMed Web of Science ®Google Scholar
• Lamy A, Gobet F, Laurent M et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J. Urol.176(6 Pt 1), 2686–2689 (2006).
   PubMed Web of Science ®Google Scholar
• Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med.331(19), 1259–1264 (1994).
   PubMed Web of Science ®Google Scholar
• Haitel A, Posch B, El-Baz M et al. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. J. Urol.165(5), 1481–1487 (2001).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J, Nogueira-March JL. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur. Urol.41(2), 182–188; discussion 188–189 (2002).
   PubMed Web of Science ®Google Scholar
• Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol.6(9), 678–686 (2005).
   PubMed Web of Science ®Google Scholar
• Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur. Urol.38(6), 691–699; discussion 700 (2000).
   PubMed Web of Science ®Google Scholar
• Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature381(6584), 713–716 (1996).
   PubMed Web of Science ®Google Scholar
• Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature385(6612), 123–125 (1997).
   PubMed Web of Science ®Google Scholar
• Li D, Tian Y, Ma Y, Benjamin T. p150Sal2 is a p53-independent regulator of p21WAF1/CIP. Mol. Cell Biol.24(9), 3885–3893 (2004).
   PubMedGoogle Scholar
• Stein JP, Ginsberg DA, Grossfeld GD et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl Cancer Inst.90(14), 1072–1079 (1998).
   PubMed Web of Science ®Google Scholar
• Migaldi M, Sgambato A, Garagnani L et al. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin. Cancer Res.6(8), 3131–3138 (2000).
   PubMed Web of Science ®Google Scholar
• Liukkonen T, Lipponen P, Raitanen M et al. Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol. Res.28(5), 285–292 (2000).
   PubMed Web of Science ®Google Scholar
• Simon R, Struckmann K, Schraml P et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene21(16), 2476–2483 (2002).
   PubMed Web of Science ®Google Scholar
• Sanchez-Carbayo M, Socci ND, Kirchoff T et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin. Cancer Res.13(11), 3215–3220 (2007).
   PubMed Web of Science ®Google Scholar
• Clurman BE, Groudine M. The CDKN2A tumor-suppressor locus – a tale of two proteins. N. Engl. J. Med.338(13), 910–912 (1998).
   PubMedGoogle Scholar
• Tao W, Levine AJ. P19ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl Acad. Sci. USA96(12), 6937–6941 (1999).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell92(6), 725–734 (1998).
   PubMed Web of Science ®Google Scholar
• Bates S, Phillips AC, Clark PA et al. p14ARF links the tumour suppressors RB and p53. Nature395(6698), 124–125 (1998).
   PubMed Web of Science ®Google Scholar
• Kawamoto K, Enokida H, Gotanda T et al.p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem. Biophys. Res. Commun.339(3), 790–796 (2006).
   PubMed Web of Science ®Google Scholar
• Dominguez G, Silva J, Garcia JM et al. Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat. Res.530(1–2), 9–17 (2003).
   Google Scholar
• Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell65(6), 1053–1061 (1991).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Xu HJ, Ro JY et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl Cancer Inst.84(16), 1256–1261 (1992).
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Wartinger D, Petrylak D et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl Cancer Inst.84(16), 1251–1256 (1992).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Liebert M, Antelo M et al. p53 and RB expression predict progression in T1 bladder cancer. Clin. Cancer Res.4(4), 829–834 (1998).
   PubMed Web of Science ®Google Scholar
• Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res.58(6), 1090–1094 (1998).
   PubMed Web of Science ®Google Scholar
• Chatterjee SJ, George B, Goebell PJ et al. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J. Pathol.203(3), 762–770 (2004).
   PubMed Web of Science ®Google Scholar
• Osoegawa A, Yoshino I, Tanaka S et al. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J. Clin. Oncol.22(20), 4165–4173 (2004).
   PubMed Web of Science ®Google Scholar
• Polyak K, Lee MH, Erdjument-Bromage H et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell78(1), 59–66 (1994).
   PubMed Web of Science ®Google Scholar
• Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science272(5263), 877–880 (1996).
   PubMed Web of Science ®Google Scholar
• Kamai T, Takagi K, Asami H et al. Decreasing of p27Kip1 and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br. J. Cancer84(9), 1242–1251 (2001).
   PubMed Web of Science ®Google Scholar
• Franke KH, Miklosi M, Goebell P et al. Cyclin-dependent kinase inhibitor p27KIP1 is expressed preferentially in early stages of urothelial carcinoma. Urology56(4), 689–695 (2000).
   PubMed Web of Science ®Google Scholar
• Schrier BP, Vriesema JL, Witjes JA, Kiemeney LA, Schalken JA. The predictive value of p53, p27Kip1, and α-catenin for progression in superficial bladder carcinoma. Eur. Urol.50(1), 76–82 (2006).
   Google Scholar
• Bartoletti R, Cai T, Nesi G et al. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J. Surg. Res. (2007) (Epub ahead of print).
   Google Scholar
• Takagi Y, Takashi M, Koshikawa T, Sakata T, Ohshima S. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int. J. Urol.7(10), 366–372 (2000).
   Google Scholar
• Sgambato A, Migaldi M, Faraglia B et al. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int. J. Cancer97(5), 671–678 (2002).
   Google Scholar
• Oya M, Schmidt B, Schmitz-Drager BJ, Schulz WA. Expression of G1-->S transition regulatory molecules in human urothelial cancer. Jpn J. Cancer Res.89(7), 719–726 (1998).
   PubMedGoogle Scholar
• Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1–S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am. J. Clin. Pathol.122(3), 444–452 (2004).
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Requena MJ, Luque RJ et al. Cyclin D3 expression in primary Ta/T1 bladder cancer. J. Pathol.209(1), 106–113 (2006).
   Google Scholar
• Richter J, Wagner U, Kononen J et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am. J. Pathol.157(3), 787–794 (2000).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum. Pathol.37(12), 1568–1576 (2006).
   PubMed Web of Science ®Google Scholar
• Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene25(34), 4798–4811 (2006).
   PubMed Web of Science ®Google Scholar
• Evans DL, Tilby M, Dive C. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res.54(6), 1596–1603 (1994).
   Google Scholar
• Dive C, Hickman JA. Drug–target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer64(1), 192–196 (1991).
   PubMed Web of Science ®Google Scholar
• Chyle V, Pollack A, Czerniak B et al. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys.35(2), 281–287 (1996).
   Google Scholar
• Lara PC, Perez S, Rey A, Santana C. Apoptosis in carcinoma of the bladder: relation with radiation treatment results. Int. J. Radiat. Oncol. Biol. Phys.43(5), 1015–1019 (1999).
   Google Scholar
• Moonen L, Ong F, Gallee M et al. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int. J. Radiat. Oncol. Biol. Phys.49(5), 1305–1310 (2001).
   Google Scholar
• Kelly JD, Williamson KE, Irvine AE et al. Apoptosis and its clinical significance for bladder cancer therapy. BJU Int.83(1), 1–10 (1999).
   Google Scholar
• Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene9(6), 1799–1805 (1994).
   PubMed Web of Science ®Google Scholar
• Korsmeyer SJ. Regulators of cell death. Trends Genet.11(3), 101–105 (1995).
   PubMed Web of Science ®Google Scholar
• Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science275(5303), 1132–1136 (1997).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A et al. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Lett.250(2), 292–299 (2007).
   PubMedGoogle Scholar
• Shiina H, Igawa M, Urakami S et al. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J. Clin. Pathol.49(5), 395–399 (1996).
   PubMedGoogle Scholar
• Karam JA, Lotan Y, Karakiewicz PI et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol.8(2), 128–136 (2007).
   PubMed Web of Science ®Google Scholar
• Pollack A, Wu CS, Czerniak B et al. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin. Cancer Res.3(10), 1823–1829 (1997).
   PubMedGoogle Scholar
• Cooke PW, James ND, Ganesan R et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int.85(7), 829–835 (2000).
   PubMed Web of Science ®Google Scholar
• Giannopoulou I, Nakopoulou L, Zervas A et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol. Res.30(5), 342–345 (2002).
   Google Scholar
• Korkolopoulou P, Lazaris A, Konstantinidou AE et al. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur. Urol.41(3), 274–283 (2002).
   PubMedGoogle Scholar
• Yuan SY, Hsu SL, Tsai KJ, Yang CR. Involvement of mitochondrial pathway in Taxol-induced apoptosis of human T24 bladder cancer cells. Urol. Res.30(5), 282–288 (2002).
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim JK, Kim KD et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett.237(1), 56–66 (2006).
   PubMed Web of Science ®Google Scholar
• Altieri DC. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer3(1), 46–54 (2003).
   PubMed Web of Science ®Google Scholar
• Li F. Survivin study: what is the next wave? J. Cell Physiol.197(1), 8–29 (2003).
   PubMed Web of Science ®Google Scholar
• Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett.249(1), 49–60 (2007).
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang G, Wei J, Wen X. Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer. Indian J. Med. Sci.59(6), 235–242 (2005).
   PubMedGoogle Scholar
• Schultz IJ, Wester K, Straatman H et al. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur. Urol.51(2), 416–422; discussion 422–413 (2007).
   PubMed Web of Science ®Google Scholar
• Als AB, Dyrskjot L, von der Maase H et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res.13(15 Pt 1), 4407–4414 (2007).
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1–S modulators (p53, p21Waf1, p27Kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur. Urol.45(5), 606–612 (2004).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod. Pathol.20(4), 445–459 (2007).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Tokunaga H, Zhou J et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol.22(6), 1014–1024 (2004).
   PubMed Web of Science ®Google Scholar
• Chatterjee SJ, Datar R, Youssefzadeh D et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol.22(6), 1007–1013 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia del Muro X, Condom E, Vigues F et al. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer100(9), 1859–1867 (2004).
   PubMedGoogle Scholar
• Tzai TS, Tsai YS, Chow NH. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Urol. Oncol.22(2), 112–118 (2004).
   PubMed Web of Science ®Google Scholar
• Galmozzi F, Rubagotti A, Romagnoli A et al. Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer. J. Cancer Res. Clin. Oncol.132(12), 757–764 (2006).
   Google Scholar
• Ioachim E, Michael M, Stavropoulos NE et al. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21Waf1/Cip1 and p27Kip1 in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features. Urol. Int.73(1), 65–73 (2004).
   Google Scholar
• Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol.24(5), 778–789 (2006).
   PubMed Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature422(6928), 198–207 (2003).
   PubMed Web of Science ®Google Scholar
• Lee KH. Proteomics: a technology-driven and technology-limited discovery science. Trends Biotechnol.19(6), 217–222 (2001).
   PubMed Web of Science ®Google Scholar
• Liu W, Guan M, Wu D et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur. Urol.47(4), 456–462 (2005).
   PubMed Web of Science ®Google Scholar
• Gorelik E, Landsittel DP, Marrangoni AM et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev.14(4), 981–987 (2005).
   PubMed Web of Science ®Google Scholar